Stockreport

UCB Initiates Phase 1b US-Based Multicenter Clinical Trial in Parkinson’s Disease Patients with UCB0599, a Compound Arising from the Neuropore-UCB Collaboration

UCB SA UNSP/ADR  (UCBJY) 
NASDAQ:AMEX Investor Relations: ucb.com/investors
PDF SAN DIEGO--(BUSINESS WIRE)-- Neuropore Therapies, Inc. announced today that partner UCB initiated a multicenter clinical trial in Parkinson’s disease [Read more]